The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis [0.03%]
腹腔注射重组artLCMV可长期表达并有效抑制腹膜肿瘤模型的小鼠体内肿瘤生长
Celia Gomar,Aline Risson,Leire Arrizabalaga et al.
Celia Gomar et al.
Peritoneal carcinomatosis remains a challenging clinical condition with limited therapeutic options. In this study, we evaluated the efficacy of a recombinant artLCMV platform encoding tumor antigens and immune-stimulatory molecules in prec...
Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes [0.03%]
人cDC1可通过CD226改善终末期衰竭的肿瘤浸润淋巴细胞的功能
Liam O&#x;Brien,Irina Buckle,Ingrid M Leal-Rojas et al.
Liam O&#x;Brien et al.
Prevention or reversal of T cell exhaustion is a major objective of cancer immunotherapy. However, few models exist to generate, characterize and modulate exhausted human T cells, particularly within solid tumors in vivo, which likely hampe...
Correction [0.03%]
改正通知书
Published Erratum
Oncoimmunology. 2025 Dec;14(1):2517490. DOI:10.1080/2162402X.2025.2517490 2025
Cancer cells accelerate exhaustion of persistently activated mouse CD4+ T cells [0.03%]
癌细胞加速持久活化的CD4+T淋巴细胞耗竭
Malgorzata Stachowiak,William J Becker,Purevdorj B Olkhanud et al.
Malgorzata Stachowiak et al.
Most exhaustion studies have focused on CD8+ T cells. Here, we demonstrated reciprocal growth inhibition of CD4+ T cells and colorectal cancer cells, which induced the expression of PD-1, PD-L1, and PD-L2 in CD4+ T cells. The accelerated ex...
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma [0.03%]
用于治疗胶质母细胞瘤的universal-targeting mSA2 CAR-T细胞的应用
Alexandros Kourtesakis,Eileen Bailey,Hiu Nam Hannah Chow et al.
Alexandros Kourtesakis et al.
Glioblastoma (GB) remains refractory to chimeric antigen receptor (CAR)-T cell therapy, mainly attributed to tumor heterogeneity and antigen escape. CAR-T cells utilizing monomeric streptavidin-2 (mSA2) instead of a traditional target bindi...
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases [0.03%]
针对突变型p53的CD8 TCR疗法结合CD4 TCR预防癌症复发和微转移病灶的发展
Vasiliki Anastasopoulou,Hans Schreiber,Ching-En Lee et al.
Vasiliki Anastasopoulou et al.
Relapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. We present the spontaneously metastasizing tumor model Ag104A to advance mp53-specific ...
PARP inhibitors accumulate B7-H3 on fibroblasts via blocking autophagic flux to potentiate immune evasion in ovarian cancer [0.03%]
PARP抑制剂通过阻断自噬流在卵巢癌中使成纤维细胞积累B7-H3以增强免疫逃逸
Tian Fang,Yu Xia,Ying Li et al.
Tian Fang et al.
Besides targeting tumor cells via canonical synthetic lethality, poly(ADP-ribose) polymerase inhibitors (PARPis) can remodel tumor immune microenvironment (TIME), which then affects PARPis' anti-tumor capabilities. However, exact function o...
Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models [0.03%]
局部细胞因子递送与系统性重组артлcmv免疫相结合可增强多种临床肿瘤模型的抗肿瘤疗效
Kimberly Pojar,Diana Reckendorfer,Judith Strauss et al.
Kimberly Pojar et al.
Among the plethora of cancer immune evasion mechanisms, T-cell-inhibiting factors within the tumor microenvironment impose a major challenge for the development of novel immunotherapies. Strategies to overcome immunosuppression and remodel ...
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) [0.03%]
NSCLC患者围手术期化疗的外周记忆B细胞群维持和长期生存（NADIM试验）
Belén Sierra Rodero,Cristina Martínez-Toledo,Ernest Nadal et al.
Belén Sierra Rodero et al.
Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives to...
Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin [0.03%]
无心脏毒性的蒽环类抗生素阿克拉霉素的免疫依赖性抗肿瘤效应
Giulia Cerrato,Allan Sauvat,Mahmoud Abdellatif et al.
Giulia Cerrato et al.
Aclarubicin (also called aclacinomycin A) is an antineoplastic from the anthracycline class that is used in China and Japan but not in Europe nor in the USA. Aclarubicin induces much less DNA damage than the classical anthracyclines doxorub...